{
}
Novartis AG, which focuses on healthcare products, has 13.12% of its stock owned by institutional investors. The company recently received mixed ratings from analysts, with a consensus rating of "Hold" and a price target of $123.38. Despite beating earnings expectations, Novartis shares have faced downward pressure, reflecting a cautious outlook among investors.
UBS Group experienced a slight decline in share price, dropping 0.22% to EUR 31.95 on February 14, 2025. The bank has been actively managing its portfolio, downgrading Novartis shares from "Buy" to "Neutral" and adjusting the price target, while also raising AppLovin's target significantly. With a market capitalization of 110.6 billion euros, UBS remains a key player in global financial services, prompting shareholders to consider their next moves.
UBS shares have been removed from a model portfolio by a strategist, following a recent reinstatement by another analyst. The Swiss market shows mixed performance, with Givaudan gaining slightly while Sonova and Dätwyler face declines. Notable updates include Galderma receiving EMA marketing authorization and Novartis gaining FDA orphan drug designation for Ianalumab.
Novartis AG is experiencing a "sharp deceleration" in growth projected by mid-2025, according to UBS. The company's sales are primarily driven by oncology (29.3%), immunology (18.5%), and cardiovascular, renal, and metabolic diseases (17%), with contract manufacturing accounting for 25.8%. Geographically, sales are distributed as follows: USA (42%), Europe (30.9%), Asia-Africa-Australasia (20%), and Canada and Latin America (7.1%).
Novartis AG, a leading pharmaceutical company, is projected to experience a significant slowdown in growth by mid-2025. Its sales are primarily derived from oncology (29.3%), immunology (18.5%), and cardiovascular, renal, and metabolic diseases (17%), with a notable 25.8% from contract manufacturing. Geographically, 42% of sales come from the USA, followed by Europe (30.9%) and Asia/Africa/Australasia (20%).
Novartis experienced a significant decline in its share price after UBS downgraded its recommendation from "buy" to "neutral," citing concerns over patent expiries for key products like Entresto and Tasigna. The price target was also reduced from 111 to 104 Swiss francs, contributing to a 0.5% drop in shares, contrasting with a 1.1% gain in the SMI index. UBS maintains that Novartis's product portfolio still holds growth potential, but this is now reflected in consensus forecasts.
Novartis' share price declined by 0.5% after UBS downgraded its recommendation from "buy" to "neutral," reducing the price target from 111 to 104 Swiss francs. The analyst noted that while the company's product portfolio has growth potential, upcoming patent expiries for key drugs like Entresto and Tasigna are expected to slow growth significantly this year.
Novartis experienced a significant decline in its share price after UBS downgraded its recommendation from "buy" to "neutral," reducing the price target from 111 to 104 Swiss francs. The analyst noted that while the company's product portfolio has growth potential, upcoming patent expiries for key drugs like Entresto and Tasigna are expected to slow growth this year. Following this news, Novartis shares fell by 0.5%, contrasting with a 1.1% gain in the SMI index.
Novartis experienced a significant decline in its share price after UBS downgraded its recommendation from 'buy' to 'neutral', reducing the price target from 111 to 104 Swiss francs. The downgrade reflects concerns over upcoming patent expiries for key products, which are expected to slow growth this year. Following this news, Novartis shares fell by 0.5%, contrasting with a 1.1% gain in the SMI index.
UBS has adjusted its ratings on key European pharmaceutical companies, downgrading Novartis to Neutral due to concerns over patent expirations and a limited pipeline, while upgrading Roche to Buy, citing strong growth prospects and a robust pipeline. AstraZeneca also received a Buy upgrade, driven by its sector-leading pipeline potential, with both companies seeing significant increases in their price targets.
Novartis AG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
novartis stock analysis shows mixed ratings from analysts and institutional investors
14:41 14.02.2025
ubs shares see slight decline as investment strategies shift
11:02 14.02.2025
market updates shares performance and analyst recommendations in europe and us
Vetropack Holding AG
Nestlé S.A.
Sonova R
SGS SA
Novartis AG
Lukas Ruflin
Mensur Pocinci
Rainer-Marc Frey
Show more
08:11 14.02.2025
novartis anticipates significant growth slowdown by mid 2025 according to ubS
18:10 13.02.2025
Novartis anticipates significant growth slowdown by mid 2025
18:03 13.02.2025
Novartis share price drops as UBS downgrades stock recommendation to neutral
16:36 13.02.2025
Novartis share price declines after UBS downgrades stock recommendation to neutral
16:36 13.02.2025
Novartis shares decline as UBS downgrades stock recommendation to neutral
16:31 13.02.2025
Novartis shares decline as UBS downgrades stock recommendation to neutral
16:31 13.02.2025
ubs adjusts ratings on european pharma stocks novartis downgraded roche upgraded
13:14 13.02.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Central Bank Actions
Retail and Consumer Goods
CEO Changes
GDP Growth & Recession Forecasts
Global Trade Developments
Financial Scams and Security
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Market Analysis and Predictions
Government Policies
Government Economic Policies
Supply Chain Management
Startups & Entrepreneurship
Domestic Politics
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Bank of America Corporation
Barclays PLC
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Microsoft Corporation
Credit Suisse Strategic Income I
NVIDIA Corporation
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
End Federal Reserve USD
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Australian Dollar
Canadian Dollar
United Arab Emirates Dirham
Indonesian Rupiah
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Hong Kong Dollar
Mexican Peso
Malaysian Ringgit
Vietnamese Đồng
People: